ReviewBiotechnology journal2008
RNA interference: an emerging generation of biologicals.
Review in Biotechnology journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Article
- CRISPR Gene Editing in Yeast: An Experimental Protocol for an Upper-Division Undergraduate Laboratory Course.Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology · 2018Article
- MicroRNA in Glioblastoma: An Overview.International journal of genomics · 2017Review
- Targeting MACC1 by RNA interference inhibits proliferation and invasion of bladder urothelial carcinoma in T24 cells.International journal of clinical and experimental pathology · 2015Article
- The effects of p38 gene silencing on breast cancer cells.Molecular biology reports · 2014Article
- Optochemical control of deoxyoligonucleotide function via a nucleobase-caging approach.Accounts of chemical research · 2014Article
- Optochemical control of RNA interference in mammalian cells.Nucleic acids research · 2013Article
- siRNA-mediated knock-down of DFF45 amplifies doxorubicin therapeutic effects in breast cancer cells.Cellular oncology (Dordrecht, Netherlands) · 2013Article
- Non-Viral Delivery and Therapeutic Application of Small Interfering RNAs.Acta naturae · 2013Article
- Current translational and clinical practices in hematopoietic cell and gene therapy.Cytotherapy · 2012Review
- Local pulmonary immunotherapy with siRNA targeting TGFβ1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice.Tuberculosis (Edinburgh, Scotland) · 2011Article
- Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery.Bioconjugate chemistry · 2010Article
- New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma.Pharmaceutical research · 2010Article
- Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis.American journal of respiratory cell and molecular biology · 2009Article
- Sequence determinants of innate immune activation by short interfering RNAs.BMC immunology · 2009Article
- Inhibition of vaccinia virus replication by two small interfering RNAs targeting B1R and G7L genes and their synergistic combination with cidofovir.Antimicrobial agents and chemotherapy · 2009Article
- Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease.Pharmacology & therapeutics · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA interference (RNAi) is a mechanism displayed by most eukaryotic cells to rid themselves of foreign double-stranded RNA molecules. RNAi has now been demonstrated to function in mammalian cells to alter gene expression, and has been used as a means for genetic discovery as well as a possible strategy for genetic correction. RNAi was first described in animal cells by Fire and colleagues in the nematode, Caenorhabditis elegans. Knowledge of RNAi mechanism in mammalian cell in 2001 brought a storm in the field of drug discovery. During the past few years scientists all over the world are focusing on exploiting the therapeutic potential of RNAi for identifying a new class of therapeutics. The applications of RNAi in medicine are unlimited because all cells possess RNAi machinery and hence all genes can be potential targets for therapy. RNAi can be developed as an endogenous host defense mechanism against many infections and diseases. Several studies have demonstrated therapeutic benefits of small interfering RNAs and micro RNAs in animal models. This has led to the rapid advancement of the technique from research discovery to clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.